Header links
Intranet
Donate now
image/svg+xml Map
Contact us

María Bermúdez Ramos

María Bermúdez Ramos

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca
María Bermúdez Ramos

María Bermúdez Ramos

María Bermúdez Ramos

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Related news

Dr. Raul Herance

We develop a method to diagnose fatty liver in a quantitative and non-invasive way

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Pacient d'un assaig clínic a la consulta

VHIR exceeds 700 active clinical trials to achieve new therapies for patients

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Grup de Malalties Hepàtiques del VHIR

A clinical trial has led to approval of the first drug for advanced fatty liver disease

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

See more

Related professionals

María Puigcerver Mas

María Puigcerver Mas

Physiology and Pathophysiology of the Digestive Tract
Read more
Andrea Onieva Salgado

Andrea Onieva Salgado

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Joaquin Ruiz Altarejo

Joaquin Ruiz Altarejo

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria Martinez Martinez

Maria Martinez Martinez

Main researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.